New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
16:08 EDTXNCRXencor reports Q2 EPS (16c), consensus (19c)
Reports Q2 revenue $824K, consensus $1.44M. Based on current operating plans, Xencor expects to have sufficient cash to fund research and development programs and operations through 2016, and maintains the 2014 year-end cash and cash equivalents estimate of approximately $54.0M.
News For XNCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
08:03 EDTXNCRXencor and Novo Nordisk partner for novel drug development
Subscribe for More Information
December 7, 2014
14:59 EDTXNCRMorphoSys and Xencor publish final results from Phase 1/2a trial of MOR208
MorphoSys and Xencor (XNCR) announced the publication of final results of a Phase 1/2a trial evaluating MOR208 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia. MOR208 is a potent anti-CD19 antibody with a proprietary modification to the Fc portion that is being developed to treat B-cell malignancies. MOR208 was in-licensed by MorphoSys from Xencor in 2010.The results demonstrate that the drug was well tolerated and achieved durable responses in a high risk and poor prognosis patient population with significant progression-free survival achieved.
December 6, 2014
09:38 EDTXNCRXencor to hold a meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use